These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29349077)

  • 1. The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma.
    Wan X; Liu R; Li Z
    Biomed Res Int; 2017; 2017():5356737. PubMed ID: 29349077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
    Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
    Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
    Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
    Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
    J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NRAS mutant melanoma--undrugable?
    Posch C; Ortiz-Urda S
    Oncotarget; 2013 Apr; 4(4):494-5. PubMed ID: 23660168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
    Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
    Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma.
    Fan Y; Liang X; Yu D
    Aging (Albany NY); 2021 Oct; 13(19):23036-23071. PubMed ID: 34613934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of NRAS isoforms in Chinese melanoma patients.
    Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
    Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
    Guo H; Cheng Y; Martinka M; McElwee K
    Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
    Wu ZS; Cheng XW; Wang XN; Song NJ
    Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.